AR108939A1 - Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este - Google Patents

Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este

Info

Publication number
AR108939A1
AR108939A1 ARP170101831A ARP170101831A AR108939A1 AR 108939 A1 AR108939 A1 AR 108939A1 AR P170101831 A ARP170101831 A AR P170101831A AR P170101831 A ARP170101831 A AR P170101831A AR 108939 A1 AR108939 A1 AR 108939A1
Authority
AR
Argentina
Prior art keywords
delivery system
transdermal delivery
methylphenidate
methods
transdermal administration
Prior art date
Application number
ARP170101831A
Other languages
English (en)
Inventor
Catherine Lee
Taijung Wu
Shen-Yung Kao
Original Assignee
Taho Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taho Pharmaceuticals Ltd filed Critical Taho Pharmaceuticals Ltd
Publication of AR108939A1 publication Critical patent/AR108939A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D153/00—Coating compositions based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Coating compositions based on derivatives of such polymers
    • C09D153/02—Vinyl aromatic monomers and conjugated dienes
    • C09D153/025—Vinyl aromatic monomers and conjugated dienes modified

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymers & Plastics (AREA)

Abstract

Un sistema de administración transdérmica que comprende metilfenidato o su sal como ingrediente activo. También métodos para administrar una cantidad terapéuticamente eficaz de metilfenidato a un sujeto para el tratamiento de una condición patológica. Esta condición patológica incluye una afección neurológica, tal como el trastorno por déficit de atención (ADD) y/o el trastorno por déficit de atención con hiperactividad (ADHD). También kits que incluyen el sistema de administración transdérmica y métodos para fabricar y usar el sistema de administración transdérmica. Reivindicación 1: Un sistema de administración transdérmica que comprende: (i) una capa adhesiva de silicona; y (ii) una capa con matriz que contiene el fármaco que comprende: (a) metilfenidato o su sal aceptable desde el punto de vista farmacéutico; y (b) un polímero a base de caucho, que comprende un mejorador de la pegajosidad sintético hidrogenado, en donde el sistema de administración transdérmica tiene una velocidad de flujo que varía de alrededor de 6 mg/cm²/h a 100 mg/cm²/h, entre 2 - 18 horas después del inicio del tratamiento. Reivindicación 2: El sistema de administración transdérmica de acuerdo con la reivindicación 1, en donde el polímero a base de caucho es caucho de copolímero en bloque de estireno-butadieno. Reivindicación 3: El sistema de administración transdérmica de acuerdo con cualquiera de las reivindicaciones anteriores, que consiste esencialmente de una capa de soporte, la capa adhesiva de silicona, la capa con matriz que contiene el fármaco y un protector antiadherente.
ARP170101831A 2016-06-30 2017-06-30 Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este AR108939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662357316P 2016-06-30 2016-06-30

Publications (1)

Publication Number Publication Date
AR108939A1 true AR108939A1 (es) 2018-10-10

Family

ID=60787668

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101831A AR108939A1 (es) 2016-06-30 2017-06-30 Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este

Country Status (8)

Country Link
US (3) US9980921B2 (es)
EP (1) EP3448778A4 (es)
JP (1) JP7005539B2 (es)
KR (1) KR20190039692A (es)
CN (1) CN109689527B (es)
AR (1) AR108939A1 (es)
TW (1) TW201803563A (es)
WO (1) WO2018005593A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof
JP2023501370A (ja) * 2019-11-07 2023-01-18 アミリス， インコーポレイテッド カンナビノイドを皮膚に送達するための組成物および方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102291A1 (en) 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
EP1663179A1 (en) 2003-07-21 2006-06-07 Noven Pharmaceuticals, Inc. Composition and method for controlling drug delivery from silicone adhesive blends
WO2006041911A2 (en) 2004-10-08 2006-04-20 Noven Pharmaceuticals, Inc. Device transdermal administration of drugs including acrylic polymers
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
JP5568133B2 (ja) * 2009-08-18 2014-08-06 ダウ コーニング コーポレーション 多層経皮パッチ
WO2011034323A2 (en) * 2009-09-16 2011-03-24 Samyang Corporation Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system
US20110200663A1 (en) 2010-02-12 2011-08-18 Nitto Denko Corporation Methylphenidate patch preparation
US9072682B2 (en) * 2012-12-31 2015-07-07 Mylan Inc. Transdermal dosage form for low-melting point active agent
AR095258A1 (es) * 2013-03-14 2015-09-30 Noven Pharma Composiciones transdérmicas de metilfenidato con adhesivos a base de goma
US9682068B2 (en) 2013-05-20 2017-06-20 Mylan Inc. Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders
JP6689254B2 (ja) 2014-07-31 2020-04-28 ノーヴェン ファーマシューティカルズ インコーポレイテッド 経皮薬物送達組成物のためのシリコーン含有アクリルポリマー
US9980921B2 (en) * 2016-06-30 2018-05-29 Taho Pharmaceuticals Ltd. Transdermal delivery system containing methylphenidate or its salts and methods thereof

Also Published As

Publication number Publication date
CN109689527A (zh) 2019-04-26
JP7005539B2 (ja) 2022-02-04
EP3448778A4 (en) 2020-01-08
WO2018005593A1 (en) 2018-01-04
TW201803563A (zh) 2018-02-01
US20180000746A1 (en) 2018-01-04
US20180263923A1 (en) 2018-09-20
EP3448778A1 (en) 2019-03-06
CN109689527B (zh) 2021-02-19
US9980921B2 (en) 2018-05-29
US10537532B2 (en) 2020-01-21
JP2019524698A (ja) 2019-09-05
US20180263922A1 (en) 2018-09-20
KR20190039692A (ko) 2019-04-15
US10420733B2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
CY1120283T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση ριβαστιγμινης ή παραγωγων αυτης
AR093481A1 (es) Parche de varios dias para la administracion transdermica de rotigotina
PH12015501169A1 (en) Transdermal delivery system
AR095259A1 (es) Composiciones y métodos para la administración transdérmica de fármacos de amina terciaria
AR073704A1 (es) Sistema de administracion transdermal de droga para principios activos liquidos que tiene una capa de matriz adhesiva que incluye un ingrediente farmaceutico activo que es seleccionado entre selegilina y rivastigmina
BR112015024271A2 (pt) sistema de fornecimento transdérmico
AR070031A1 (es) Sistemas de administracion transdermicos de droga ketotifen y metodos para el tratamiento de enfermedades oftalmicas
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
AR072492A1 (es) Dispositivo y administracion transdermica de estrogeno
MX2019007389A (es) Sistema terapeutico transdermico que contiene asenapina y polisiloxano o poliisobutileno.
AR093118A1 (es) Composiciones y metodos para la administracion transdermica de anfetamina
CO6640335A2 (es) Tratamiento terapéutico para síndrome metabólico, diabetes de tipo 2, obesidad o prediabetes
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
CR9737A (es) Dispositivos de administracion transdermicas de farmacos que contienen o-desmetilvenlafaxina (odv) sus sales.
AR108939A1 (es) Sistema de administración transdérmica que contiene metilfenidato o sus sales, y métodos de este
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
DOP2014000171A (es) Sistema para la administración de fármacos
ECSP22036502A (es) Inhibidores del factor d del complemento para administraci?n oral
BR112014004635A2 (pt) sistema terapêutico transdérmico para cloridrato de ácido 5-aminolavulínico
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
BR112022012111A2 (pt) Sistema terapêutico transdérmico contendo agomelatina
MX2021012709A (es) Sistema terapeutico transdermico.
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel

Legal Events

Date Code Title Description
FB Suspension of granting procedure